Autoimmune Diseases  >>  Lantus (insulin glargine)  >>  Phase 3
Welcome,         Profile    Billing    Logout  

13 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Lantus (insulin glargine) / Sanofi
NCT00546702: Glulisine + Lantus in Type I Patients

Completed
3
142
RoW
Insuline Glulisine
Sanofi
Diabetes Mellitus, Type 1
02/05
02/05
NCT00545337: Glulisine + Lantus in Type I Patients

Completed
3
60
RoW
Insuline glulisine
Sanofi
Diabetes Mellitus, Type 1
06/05
06/05
NCT00272090: Insulin Glargine in Type 1 Diabetes Mellitus

Completed
3
489
Europe
Insulin glargine
Sanofi
Diabetes Mellitus, Type 1
12/05
12/05
NCT00115570: Comparison of the Ability of Glulisine With Lispro to Control Type 1 Diabetes Mellitus in Children and Adolescents

Completed
3
572
US
Insulin glulisine, apidra, insulin lispro, insulin glargine, NPH insulin
Sanofi
Diabetes Mellitus, Insulin-Dependent
11/06
11/06
NCT00397553: Insulin Glulisine, Diabetes Mellitus Type 1

Completed
3
104
RoW
Insulin glulisine
Sanofi
Diabetes Mellitus, Type 1
12/07
 
VARIABILITE, NCT00271284: Efficacy Study on the Control of Blood Glucose Concentration in Type 1 Diabetic Patients

Completed
3
88
Europe
insulin glulisine / insulin glargine, insulin glulisin / insulin detemir
Sanofi
Diabetes Mellitus, Type 1
09/08
09/08
PRESCHOOL, NCT00993473 / 2009-011231-12: 6-month Comparison of Morning Lantus Versus Neutral Protamine Hagedorn Insulin in Young Children With Type 1 Diabetes

Checkmark P3 data - EASD
Jul 2012 - Jul 2012: P3 data - EASD
Completed
3
125
US, Europe, RoW
Insulin glargine (HOE901), Lantus®, Neutral Protamine Hagedorn (NPH) insulin, Insulin lispro, Humalog®
Sanofi
Type 1 Diabetes Mellitus
03/11
03/11
ELEMENT 1, NCT01421147 / 2011-000829-73: A Study in Adults With Type 1 Diabetes

Completed
3
536
Japan, US, Europe, RoW
LY2963016, Lantus, Insulin Lispro
Eli Lilly and Company, Boehringer Ingelheim
Diabetes Mellitus, Type 1
08/12
04/13
EDITION IV, NCT01683266 / 2012-001524-35: Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 1 Diabetes Mellitus

Checkmark From EDITION IV trial for diabetes
Dec 2013 - Dec 2013: From EDITION IV trial for diabetes
Completed
3
549
Japan, US, Canada, Europe
HOE901-U300 (Insulin glargine new formulation), Lantus (Insulin glargine)
Sanofi
Type 1 Diabetes Mellitus
09/13
03/14
EDITION JP I, NCT01689129: Comparison of a New Formulation of Insulin Glargine With Lantus® in Japanese Patients With Type 1 Diabetes Mellitus

Checkmark EDITION JP I
Dec 2013 - Dec 2013: EDITION JP I
Checkmark EDITION JP I
Dec 2013 - Dec 2013: EDITION JP I
Completed
3
243
Japan
Insulin glargine new formulation (HOE901), Insulin glargine (HOE901) (Lantus), Lantus
Sanofi
Type 1 Diabetes Mellitus
10/13
04/14
Lantus-P-CN, NCT01223131 / 2014-004640-35: Efficacy and Safety of Insulin Glargine Versus. Neutral Protamine Hagedorn (NPH) Insulin in Children With Type 1 Diabetes Above 6 Years Old.

Completed
3
162
RoW
Insulin glargine (HOE901), NPH insulin
Sanofi
Type 1 Diabetes Mellitus
03/14
03/14
MK-1293-003, NCT02059161 / 2011-003971-12: A Study of the Safety and Efficacy of MK-1293 Compared to Lantus™ in Participants With Type 1 Diabetes Mellitus (T1DM)

Completed
3
508
NA
MK-1293, Lantus™, Insulin glargine, Prandial Insulin
Merck Sharp & Dohme LLC
Type 1 Diabetes Mellitus
05/15
11/15
SORELLA1, NCT02273180 / 2013-002945-12: Comparison of SAR342434 to Humalog as the Rapid Acting Insulin in Adult Patients With Type 1 Diabetes Mellitus Also Using Insulin Glargine

Completed
3
507
Japan, US, Europe, RoW
SAR342434, Humalog, Insulin Lispro, Insulin glargine HOE901, Lantus
Sanofi
Type 1 Diabetes Mellitus
12/15
07/16

Download Options